In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 2213-63-0, name is 2,3-Dichloroquinoxaline, introducing its new discovery. Product Details of 2213-63-0
The present invention relates to certain certain fused tricyclic heteroaryl rings compounds of the Formula (I) (also referred to herein as the “”Fused Tricyclic Compounds””), wherein M, Q, U, W, X, Y, Z, R1, R2, and R3, and rings C and D are as herein described. The present invention also provides compositions comprising at least one Fused Tricyclic Compound, and use of such compounds in the treatment of central nervous system diseases or disorders such as Parkinson”s disease.
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 2213-63-0, and how the biochemistry of the body works.Product Details of 2213-63-0
Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1211 | ChemSpider